NCT06156878View on ClinicalTrials.gov

PD-1 Inhibitor Plus Anti-EGFR Therapy And Radiotherapy in Locally Advanced NPC Resistant to Induction Chemotherapy

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

August 1, 2022

Primary Completion Date

August 31, 2025

Study Completion Date

August 31, 2025

Conditions
Nasopharyngeal Carcinoma
Interventions
COMBINATION_PRODUCT

Anti-EGFR and PD-1 inhibitor arm

Drug: PD-1 inhibitor and anti-EGFR monoclonal antibody The patients will receive radiotherapy (66-70.4Gy) combined with PD-1 inhibitor (every 3 weeks) and anti-EGFR monoclonal antibody (every 1 week). The specific treatment description is included in arm description.

Trial Locations (1)

200032

RECRUITING

Eye & ENT Hospital of Fudan University, Shanghai

All Listed Sponsors
lead

Fudan University

OTHER